What does this research mean for the field?

CRISPR-Cas genome editing, particularly when integrated with immunotherapy, natural product pharmacology, and machine learning, offers a transformative approach to overcoming the limitations of traditional cancer therapies. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the therapeutic mechanisms, ongoing translational challenges, and emerging pharmacological synergies of CRISPR-Cas gene-editing platforms in oncology.

September 5, 2026Next NanotechnologyOpen Access

The inspiration of CRISPR-Cas: Interface of nature with a pharmacy: A compatible horizon of cancer treatment

View Full Paper

Ask AI

Bookmark

Authors

KKKarmvir Kaur SCShivani Chandel RSRajveer Singh

Discussion

Member takes

Overview

Review highlights CRISPR-Cas genome editing advances and delivery strategies across diverse cancers, indicating a potential shift toward precision oncology.

Key Points

To review the therapeutic mechanisms, ongoing translational challenges, and emerging pharmacological synergies of CRISPR-Cas gene-editing platforms in oncology.
Synthesized recent advances in CRISPR-Cas technologies, including base and prime editing, multiplex immune effector cell engineering, and functional genomic screens.
Evaluated primary translational obstacles, such as in vivo delivery efficiency, off-target mutagenesis, and host immunogenicity, alongside modern optimization approaches.
CRISPR-Cas tools enable precise oncogene correction, generation of universal allogeneic cell therapies, and identification of synthetic lethal vulnerabilities with decreased off-target profiles.
Emerging integration of non-viral nanocarriers, high-fidelity Cas variants, predictive machine learning models, and natural product pharmacology systematically enhances editing durability and safety.

Cite This Study

Kaur et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4606b95aff0620ec0c6 https://doi.org/10.1016/j.nxnano.2026.100741

View Full Paper

Ask AI

Bookmark

September 5, 2026Next NanotechnologyOpen Access

The inspiration of CRISPR-Cas: Interface of nature with a pharmacy: A compatible horizon of cancer treatment

View Full Paper

Ask AI

Bookmark

Authors

KKKarmvir Kaur SCShivani Chandel RSRajveer Singh

Discussion

Member takes

Overview

Review highlights CRISPR-Cas genome editing advances and delivery strategies across diverse cancers, indicating a potential shift toward precision oncology.

Key Points

To review the therapeutic mechanisms, ongoing translational challenges, and emerging pharmacological synergies of CRISPR-Cas gene-editing platforms in oncology.
Synthesized recent advances in CRISPR-Cas technologies, including base and prime editing, multiplex immune effector cell engineering, and functional genomic screens.
Evaluated primary translational obstacles, such as in vivo delivery efficiency, off-target mutagenesis, and host immunogenicity, alongside modern optimization approaches.
CRISPR-Cas tools enable precise oncogene correction, generation of universal allogeneic cell therapies, and identification of synthetic lethal vulnerabilities with decreased off-target profiles.
Emerging integration of non-viral nanocarriers, high-fidelity Cas variants, predictive machine learning models, and natural product pharmacology systematically enhances editing durability and safety.

Cite This Study

Kaur et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4606b95aff0620ec0c6 https://doi.org/10.1016/j.nxnano.2026.100741

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark